Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Spark/Novartis eye gene therapy nears EU market – but at what price?
Spark/Novartis eye gene therapy nears EU market – but at what price?
Pharmaforum
Spark Therapeutics
Novartis
Luxturna
gene therapy
Europe
Flag link:
Ex-Novartis Chief Joins uBiome to Help Launch Discovery and Development Business
Ex-Novartis Chief Joins uBiome to Help Launch Discovery and Development Business
CP Wire
uBiome
Joe Jimenez
microbiome
Novartis
Flag link:
NICE rejects Novartis’ CAR-T in adult lymphoma
NICE rejects Novartis’ CAR-T in adult lymphoma
Pharmaforum
NICE
UK
Novartis
CAR-T
Kymriah
NHS
diffuse large B-cell lymphoma
Flag link:
Novartis links bonuses to ethics in bid to rebuild reputation
Novartis links bonuses to ethics in bid to rebuild reputation
Reuters
Novartis
ethics
bonuses
compensation
Flag link:
Pfizer, Glaxo, Novo, Novartis plants unfazed by hurricane, resume production
Pfizer, Glaxo, Novo, Novartis plants unfazed by hurricane, resume production
Fierce Pharma
Pfizer
GSK
Novo Nordisk
Novartis
drug manufacturing
hurricanes
Flag link:
UCSD researchers identify mechanism, target in NASH
UCSD researchers identify mechanism, target in NASH
BioCentury
NASH
Novartis
Flag link:
Amgen, Sandoz begin biosimilar trial with top-selling Enbrel at stake
Amgen, Sandoz begin biosimilar trial with top-selling Enbrel at stake
Biopharma Dive
Amgen
Sandoz
Enbrel
biosimilars
Novartis
Flag link:
Novartis, Novo, Glaxo and others hunker down as hurricane sweeps in
Novartis, Novo, Glaxo and others hunker down as hurricane sweeps in
Fierce Pharma
Novartis
Novo Nordisk
Pfizer
GSK
hurricanes
Flag link:
The Curious Case Of Gleevec Pricing
The Curious Case Of Gleevec Pricing
Forbes
drug pricing
Gleevec
Novartis
Flag link:
Novartis makes it official: Alcon is moving its HQ from Texas to Geneva ahead of a spinoff
Novartis makes it official: Alcon is moving its HQ from Texas to Geneva ahead of a spinoff
Endpoints
Novartis
Alcon
Geneva
Texas
Flag link:
Mylan Strikes $463 Million Deal With Novartis for CF Product Line
Mylan Strikes $463 Million Deal With Novartis for CF Product Line
BioSpace
Mylan Labs
Novartis
cystic fibrosis
Flag link:
Gilead, Galapagos clear another PhII hurdle for filgotinib, but can they hope to catch up with Novartis’ Cosentyx?
Gilead, Galapagos clear another PhII hurdle for filgotinib, but can they hope to catch up with Novartis’ Cosentyx?
Endpoints
Gilead Sciences
Galapagos
filgotinib
Novartis
Cosentyx
ankylosing spondylitis
Flag link:
Novartis sells parts of Sandoz for $1bn
Novartis sells parts of Sandoz for $1bn
Pharmaforum
Novartis
Sandoz
M&A
dermatology
Aurobindo
Flag link:
Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US
Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US
Biopharma Dive
Novartis
Kymriah
CAR-T
UK
Flag link:
Novartis to streamline production in response to lower U.S. prices: NZZ am Sonntag
Novartis to streamline production in response to lower U.S. prices: NZZ am Sonntag
Yahoo/Reuters
Novartis
drug pricing
Flag link:
Novartis says glaucoma stent setback will not derail Alcon spin-off
Novartis says glaucoma stent setback will not derail Alcon spin-off
Yahoo/Reuters
Novartis
glaucoma
Alcon
eye health
devices
CyPass Micro-Stent
Flag link:
Novartis announces new €78m plant and 450 new jobs to manufacture Kymriah in EU
Novartis announces new €78m plant and 450 new jobs to manufacture Kymriah in EU
GoinPharma
Novartis
Europe
Kymriah
ALL
acute lymphoblastic leukemia
Flag link:
Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe
Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe
Endpoints
Novartis
CAR-T
Kymriah
drug manufacturing
Flag link:
LifeMax Acquires Rights to Orphan Drug for Netherton Syndrome from Novartis
LifeMax Acquires Rights to Orphan Drug for Netherton Syndrome from Novartis
CP Wire
LifeMax Laboratories
Novartis
BPR277
Netherton Syndrome
Flag link:
LifeMax Acquires Rights to Orphan Drug for Netherton Syndrome from Novartis
LifeMax Laboratories
Novartis
BPR277
Netherton Syndrome
Flag link:
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »